Perry George, Sayre Lawrence M, Atwood Craig S, Castellani Rudolph J, Cash Adam D, Rottkamp Catherine A, Smith Mark A
Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA.
CNS Drugs. 2002;16(5):339-52. doi: 10.2165/00023210-200216050-00006.
Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.
过渡金属铁和铜的代谢异常已被证明在各种神经退行性疾病的发病机制中起关键作用。本文深入综述了与神经退行性疾病中脑功能改变相关的金属稳态。虽然有文献证据表明过渡金属的稳态、氧化还原活性和定位发生了改变,但同样重要的是要认识到特定含铜和含铁金属酶的改变似乎在神经退行性过程中起关键作用。这些变化为识别可能发生疾病过程修饰的途径提供了机会, potentially offering opportunities for clinical intervention.随着对疾病病因学的理解不断发展,治疗疾病的工具也在不断发展。在本文中,我们不仅研究了疾病的可能机制,还研究了药物如何干预,从直接和间接抗氧化疗法到涉及基因治疗的策略。 (原文最后一句翻译稍显生硬,可能需要根据上下文进行适当润色,整体翻译尽量忠实原文。)